A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy

Trial Profile

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs V 212 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 23 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 13 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
    • 10 Jan 2017 This trial has been completed in Lithuania, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top